Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors purchased 2,129 call options on the company. This is an increase of 21% compared to the average volume of 1,755 call options.
Alto Neuroscience Trading Down 63.8 %
Alto Neuroscience stock traded down $9.27 during mid-day trading on Wednesday, hitting $5.26. The company had a trading volume of 3,905,875 shares, compared to its average volume of 267,460. Alto Neuroscience has a 12 month low of $5.08 and a 12 month high of $24.00. The stock’s 50 day moving average price is $12.33 and its two-hundred day moving average price is $12.54. The company has a current ratio of 19.85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. Research analysts expect that Alto Neuroscience will post -2.63 EPS for the current fiscal year.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on Alto Neuroscience
Institutional Investors Weigh In On Alto Neuroscience
A number of institutional investors have recently made changes to their positions in the company. Federated Hermes Inc. raised its stake in shares of Alto Neuroscience by 33.3% in the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $128,000 after purchasing an additional 3,000 shares during the last quarter. Bowie Capital Management LLC bought a new stake in shares of Alto Neuroscience in the second quarter worth approximately $462,000. TD Asset Management Inc bought a new stake in shares of Alto Neuroscience in the second quarter worth approximately $928,000. Rhumbline Advisers bought a new position in Alto Neuroscience during the second quarter valued at approximately $113,000. Finally, Bank of New York Mellon Corp purchased a new stake in Alto Neuroscience in the second quarter worth approximately $252,000.
About Alto Neuroscience
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Read More
- Five stocks we like better than Alto Neuroscience
- How to Invest in the Best Canadian StocksĀ
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What Does Downgrade Mean in Investing?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.